Seres is set to receive up to $3.6m in further non-dilutive funding from the international non-profit partnership, CARB-X.

Elevara’s first-in-class asset ERV001, a CDK4/6 inhibitor, is set to enter Phase II testing as an add-on treatment in RA.

Eli Lilly and NVIDIA will build a new supercomputer to accelerate drug discovery and shorten development cycles.

European biotechs should leverage its innovation and collaborate with Asian manufacturing hubs to secure greater investment, ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...

Leading clinicians, researchers & pharmaceutical innovators gathered to discuss the future of cancer treatment.

MHLW of Japan has granted orphan regenerative medicine product designation to Kyowa Kirin and Orchard Therapeutics’ MLD therapy..

Lifecore Biomedical and PolyPeptide Laboratories have linked to deliver an end-to-end peptide manufacturing solution for US ...

Norway's completed health tech assessments in 2025 were evaluated as positive, and raising thresholds may improve access conditions.

This year, Formulated Solutions will be attending PharmSci 360, held by the American Association of Pharmaceutical Scientists. Taking place ...